CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling

Research output: Contribution to journalJournal articleResearchpeer-review

Innate immune signaling relies on the deposition of non-degradative polyubiquitin at receptor-signaling complexes, but how these ubiquitin modifications are regulated by deubiquitinases remains incompletely understood. Met1-linked ubiquitin (Met1-Ub) is assembled by the linear ubiquitin assembly complex (LUBAC), and this is counteracted by the Met1-Ub-specific deubiquitinase OTULIN, which binds to the catalytic LUBAC subunit HOIP. In this study, we report that HOIP also interacts with the deubiquitinase CYLD but that CYLD does not regulate ubiquitination of LUBAC components. Instead, CYLD limits extension of Lys63-Ub and Met1-Ub conjugated to RIPK2 to restrict signaling and cytokine production. Accordingly, Met1-Ub and Lys63-Ub were individually required for productive NOD2 signaling. Our study thus suggests that LUBAC, through its associated deubiquitinases, coordinates the deposition of not only Met1-Ub but also Lys63-Ub to ensure an appropriate response to innate immune receptor activation.

Original languageEnglish
JournalCell Reports
Volume14
Issue number12
Pages (from-to)2846-58
Number of pages13
ISSN2211-1247
DOIs
Publication statusPublished - 29 Mar 2016
Externally publishedYes

Bibliographical note

Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

    Research areas

  • Catalytic Domain, Cell Line, Tumor, Cytokines/metabolism, Deubiquitinating Enzymes/antagonists & inhibitors, Endopeptidases/chemistry, HEK293 Cells, Humans, Immunity, Innate, Lysine/chemistry, Methionine/chemistry, Mutagenesis, Site-Directed, NF-kappa B/metabolism, RNA Interference, RNA, Small Interfering/metabolism, Receptor-Interacting Protein Serine-Threonine Kinase 2/metabolism, Signal Transduction, Ubiquitin/chemistry, Ubiquitin-Protein Ligases/antagonists & inhibitors, Ubiquitination

ID: 280718115